Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Investor Presentation (June 2022)
18 slides from Oncotelic Therapeutics's investor presentation, June 2022
Slide 1: Transformative Growth Focus
Transformative Growth Focus June 2022 W W W.O N C O T E L I C .C O M 1
Slide 2: Focus on Transformative Growth
Focus on Transformative Growth ➢ Building shareholder value through transformative growth PointR AI ➢ Asset acquisition => Asset repositioning for success => Spin off ➢ Multiple shots on goal Mateon ➢ Equity Holding re-IPO ➢ Accelerated Growth Oncotelic re-IPO as Sapu 10
Slide 3: Building Shareholder Value
Building Shareholder Value ➢ Oncotelic is building value by acquiring asset, strengthening the asset, and spinning off the asset. ➢ Oncotelic shareholder value increases as our subsidiary/partner companies grow in value • OTLC is now the proxy for coming IPO of Sapu in HK • 45% ownership / 50M in RP
Slide 4: Sapu Bioscience IPO
>» Sapu Bioscience IPO HKEx BE RAM ONCOTELIC THERAPEUTICS
Slide 5: SEHK Listing Rules / 18A Listings
SEHK Listing Rules / 18A Listings Traditional Listings Chapter 18A Listings • Listing applicant must satisfy one • Listing applicant does not need to of the three financial requirement satisfy any of the three financial tests regarding the revenue/profit requirement tests of the listing applicant
Slide 6: Chapter 18A key requirements
Chapter 18A key requirements ✓ Applicant must be "eligible and suitable" for biotech listing, meaning that: ✓ It must have developed at least one core product beyond the concept stage ✓ Core Product: A biotech product that is required by applicable laws to be evaluated and approved by a competent au
Slide 7: Past Pre-Revenue Biotech IPOs
Past Pre-Revenue Biotech IPOs Listing Date Company Amount Raised Therapeutic Area (HK$) 03/11/2020 JW (Cayman) Therapeutics 1,162.5M Oncology (hematologic cancer) 药明巨诺（开曼） (2126) 09/11/2020 RemeGen 1,595M Autoimmune 荣昌生物制药(9995) Oncology (lung and urothelial) Ophthalmic 20/11/2020 Antengene 1,393.5M
Slide 8: Treatments for Aging and Age-related Diseases
➢Treatments for Aging and Age-related Diseases 8
Slide 9: Sapu Bioscience TGF-β Platform
Sapu Bioscience TGF-β Platform • Inflammation NETs • Thrombosis ➢ Sapu has IP coverage for TGF-β antisense (OT- • Aging • Inflammation 101 as platform technology for treatment of Il-6 • Systemic cancers, viral diseases, and aging. ➢ OT-101 is active singly or in combination with TGFBIp • Inflammatio
Slide 10: Sapu Bioscience Pipeline
Sapu Bioscience Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Oncology Proleukin/ • Immunotherapy is transforming oncology OT-101 -IV Solid Tumors Clinigen especially for those who are tumor mutational burden-high (TMB-H) [≥10 OT-101-IV Mesothelioma Keytruda/ Merck mutations/megabase (mut/M
Slide 11: Targeted Revenue > 1B
Targeted Revenue > 1B • Of the top 7 cancer drugs- Keytruda, Opdivo, and Tecentriq belong to the checkpoint inhibitor class. By potentiating these drugs, OT-101 is expected to match their revenue Drug Company FDA Approval Indication 2021 Sales melanoma, NSCLC, HNSCC, classical HL, primary mediastina
Slide 12: Clinical Efficacy and Safety In Oncology
Clinical Efficacy and Safety In Oncology CLINICAL PANCREAS EFFICACY GLIOBLASTOMA MELANOMA • TGF-β Antisense platform for solid • Efficacy and Safety demonstrated in tumors deep and durable tumor >200 pts across more than 6 control company sponsored trials Active Treatment 200 180 T u m o r V o lu
Slide 13: Clinical Efficacy: Glioblastoma
Clinical Efficacy: Glioblastoma Tr e a t m e n t f a i l u r e p a t i e n t s ( r e c a l c i t r a n t t o r a d i a t i o n , s u r g e r y, a n d c h e m o ) • Objective responses were observed among the 87 evaluable patients treated with OT-101: • Best Objective Responses were: 5 CR (5.9%), 14
Slide 14: Clinical Efficacy: Pancreatic Cancer
Clinical Efficacy: Pancreatic Cancer Phase 2 - treatment failure pts/ recalcitrant to Whipple and chemo • Patient 1006: CR as far out as 77 mos • Patient 1022: OS of 40 months • Surgery: Whipple’s procedure • Surgery: Whipple’s procedure • 1st line: 5-FU/LV, Dose 425 mg/m2 • 1st line: Radiation ther
Slide 15: Clinical Efficacy: COVID
Clinical Efficacy: COVID • Large surge in TGF-beta during active COVID infection • An established role of TGF-beta in scarring and late stage post-COVID symptoms • Strong in vitro activity against SARS-COV-2 on Vero cells • Positive outcome for OT-101 in phase 2 clinical trial against COVID Oncoteli
Slide 16: Efficacy – Improved Survival
Efficacy – Improved Survival • OT-101 is well tolerated in COVID-19 pts with no observed aggravation of cytokine storm ie. increase in IL-6 or CRP. • OT-101 treatment was effective in reducing the viral load of all treated patients. Viral load reduction greater than 96% on Day 7 occurred in 17 of 19
Slide 17: Clinical Team
Clinical Team • Fatih Uckun MD PhD (CMO): Dr. Uckun is an elected Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America, the highest honor given
Slide 18: Thank You
Thank You Dr. Vuong Trieu ▪ CEO & Chairman ▪ vtrieu@oncotelic.com ▪ www.oncotelic.com
Oncotelic Therapeutics — Investor Presentation (June 2022) on 6ix